Prospects for the use of the immobilized monocomponent probiotics in children with recurrent respiratory diseases

Abstract

The aim of the study is to substantiate the clinical and laboratory efficacy of the immobilized probiotics containing not less than 50 million colony-forming units (5x107 CFU) of Bifidobacterium bifidum in one capsule in frequently ill children for the treatment of acute respiratory diseases and their prevention in preschool institutions.

Material and methods. Two hundred and two children aged from 3 to 7 years were included in the open prospective randomized post-marketing study. All children had a history of repeated respiratory diseases. The patients were observed in sanatorium, when visiting kindergartens, in hospital with acute respiratory infections and damage to the lower respiratory tract. Two equivalent parallel groups were formed in all institutions. The immobilized probiotics was used in the main group and the patients in the comparison group did not receive probiotics. Bacteriological tests of oropharyngeal smear samples and stool samples were carried out in children of both groups twice. Metabolic activity of the oropharyngeal microbiota by gas-liquid chromatography, immunoglobulins concentration in saliva and phagocytic activity of blood neutrophils were additionally studied. The children were observed for three months in catamnesis. In addition to efficacy, potential adverse events, adverse reactions and side effects were evaluated. Differences were considered statistically significant at p<0,05.

Results and discussion. The inclusion of the immobilized probiotics with Bifidobacterium bifidum helped to reduce the frequency of registration of acute respiratory infections and facilitate their course during the study and the next three months in the catamnesis. Recovery or significant trend to increase in the quantity of the regular inhabitants of oropharyngeal and intestinal microbiota, equilibration of metabolic balance of microorganisms in both loci, and increase in the indicators of nonspecific local and general immune defense are simultaneously associated with clinical improvement. There were no adverse events, adverse reactions, side effects when using the immobilized probiotics.

Conclusion. The positive results obtained make it possible to recommend the inclusion of the probiotics with Bifidobacterium bifidum, immobilized on activated charcoal particles, containing not less than 50 million colony-forming units (5x107 CFU) in one capsule, in the rehabilitation schemes of children with frequent acute respiratory infections in sanatoria, to use them in preschool institutions at seasonal peaks of respiratory morbidity, and to administrate for the treatment of acute respiratory infections with damage to the lower respiratory tract from the moment of admission to the hospital.

Keywords:frequently ill children, immobilized probiotics, Bifidobacterium bifidum, oropharyngeal and intestinal microbiota, specific and non-specific resistance

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Feklisova L.V. Prospects for the use of the immobilized monocomponent probiotics in children with recurrent respiratory diseases. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2021; 10 (2): 60-8. DOI: https://doi.org/10.33029/2305-3496-2021-10-2-60-68 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»